ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
Keyword(s):
Abstract High-dose methotrexate based chemotherapy(HD-MTX) improved outcome of primary central nervous system lymphoma(PCNSL), but the prognosis is still poor. Recent studies showing that Rituximab is very effective for systemic lymphoma, the role of Rituximab for PCNSL is unclear. 34 patients diagnosed PCNSL received HD-MTX chemotherapy adding rituximab. Response rates were 74%(20/27) for newly diagnosed PCNSL patients, 85.7%(6/7) for recurrent PCNSL patients. Major side effects were infusion reaction and respiratory infections disease. We have to compare the outcome of HD-MTX chemotherapy retrospectively.
2014 ◽
Vol 55
(11)
◽
pp. 2497-2501
◽
2011 ◽
Vol 52
(10)
◽
pp. 1882-1890
◽
2015 ◽
Vol 123
(2)
◽
pp. 237-244
◽
2010 ◽
Vol 8
(4)
◽
pp. 22-23
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. e14088-e14088